A Tumor-Specific Membrane Protein Degradation Platform via Covalent Reaction-Induced Aggregation

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Therapy

Background:

• Lysosome-targeting degradation strategies for membrane proteins often depend on specific receptors.
• Low expression of these receptors in tumor cells restricts their therapeutic utility.
• A novel approach is needed for efficient tumor-specific membrane protein degradation.

Purpose of the Study:

• To develop a novel strategy for tumor-specific membrane protein degradation that bypasses the need for specific receptors.
• To investigate the efficacy of covalent membrane protein aggregate-targeting chimeras (CMPATACs) in cancer therapy.
• To demonstrate the broad applicability of CMPATACs for degrading various cell-surface proteins.

Main Methods:

• Design and synthesis of covalent membrane protein aggregate-targeting chimeras (CMPATACs).
• Utilizing covalent reactions to irreversibly bind and aggregate specific membrane proteins.
• Investigating the lysosomal degradation pathway of aggregated membrane proteins.
• Evaluating the anticancer capacity of the CMPATAC strategy in preclinical models.

Main Results:

• CMPATACs were successfully designed to induce tumor-specific membrane protein aggregation and degradation.
• This strategy does not rely on the expression of specific lysosome-targeting receptors.
• CMPATACs demonstrated the degradation of broad-spectrum membrane proteins, including HER2, EGFR, EphA2, and ALP.
• The degradation of these proteins led to improved anticancer capacity.

Conclusions:

• CMPATACs represent a novel and effective strategy for tumor-specific membrane protein degradation.
• This approach overcomes the limitations of receptor-dependent strategies in cancer therapy.
• CMPATACs offer a promising therapeutic avenue for targeting cell-surface proteins in cancer treatment.